Tagged with MS

MSD South Africa If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the top ten. What are your aspirations? Our Aspiration is to consistently out grow the Market. With more than 10 brands…

Merck Sharp & Dohme (MSD) Romania You have only just arrived from Korea to head the Romanian operations at MSD. Just recently, you told in an interview with Medica Academica that MSD Romania enjoys a good reputation within MSD worldwide. Can you first elaborate to our readers what factors underlie this strong reputation? When I was…

IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…

Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…

MSD Mexico We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes you feel strong enough to continue growing in Mexico.” Can you please explain the thinking behind this statement, and what…

IMS Health Turkey Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS decide to separate Turkey from these regions ? Every third or fourth year, according to the growth of each country…

IMS Health Chile IMS was recently acquired by two investment funds, how has this affected the operations of the company and what changes did it bring in the Chilean context? So far, the acquisition has been beneficial for our Chilean operations. We expect bigger transformations to take place starting January 1st 2011, and…

China MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps in the country. You just arrived in China in February. The country managers we’ve met have all been here for…

MSD Brasil When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which is the trade name of Montelukast, with the Mont signifying “Montreal” where the product was developed. What will it take…

IMS Health Australia How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS since your arrival in December 2007? Having been a client gives insights into the client side, and perspective on what…

IMS Health Argentina It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been in Argentina for 35 years, working in information services. Two years ago, we started to offer our customers consulting services.…

IMS Health South Africa Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio? For us, like many other multinationals (MNCs), South Africa remains a vibrant growth market. It is a country that we…